Related Experiment Video
Updated: Oct 27, 2025
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Toward the Cure of Acute Lymphoblastic Leukemia in Children in China
Si-Liang Chen1, Hui Zhang2, Robert Peter Gale3
1Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Insights
Treatment outcomes for childhood acute lymphoblastic leukemia (ALL) in China are improving, with many centers nearing global standards. However, nationwide progress requires addressing challenges like healthcare funding and physician shortages to achieve better results for all children.
Area of Science:
- Pediatric Oncology
- Hematology
- Public Health
Background:
- Acute lymphoblastic leukemia (ALL) is a significant childhood cancer globally.
- Understanding treatment outcomes in diverse healthcare systems like China's is crucial for global progress.
- Previous data on nationwide pediatric ALL therapy outcomes in China were limited.
Purpose of the Study:
- To explore and analyze the therapeutic outcomes of childhood ALL in China.
- To compare Chinese ALL treatment results with international benchmarks.
- To identify obstacles and propose strategies for improving pediatric ALL care nationwide.
Main Methods:
- Conducted a nationwide survey of therapy outcomes for children with ALL in China.
- Compared Chinese data with global ALL treatment outcomes.
- Analyzed challenges hindering treatment progress and suggested remedial actions.
Main Results:
- Therapy outcomes at numerous Chinese pediatric cancer centers are approaching those in resource-rich countries.
- Nationwide ALL treatment outcomes in China still require significant improvement.
- Key obstacles include low clinical trial participation, inadequate healthcare funding, workforce shortages (especially pediatric hematology-oncology specialists), and socioeconomic disparities.
Conclusions:
- China has demonstrated substantial progress in treating childhood ALL.
- Addressing identified obstacles through expanded protocol-based therapy, enhanced supportive care, healthcare reforms, personnel recruitment, and international collaboration is essential.
- Future outcomes for children with ALL in China are expected to improve further.
Abstract:
This study explored results of therapy of children with acute lymphoblastic leukemia (ALL) in China, recent progress, and challenges. Included are a survey of therapy outcomes of ALL in Chinese children nationwide, comparison of these data with global ALL therapy outcomes, analyses of obstacles to improving outcomes, and suggestions of how progress can be achieved. Therapy outcomes at many Chinese pediatric cancer centers are approaching those of resource-rich countries. However, nationwide outcomes still need improvement. Obstacles include suboptimal clinical trials participation, children without adequate health care funding, human resource shortages, especially physicians expert in pediatric hematology and oncology, and social-economic disparities. We suggest how these obstacles have been and continue to be remedied including expanded access to protocol-based therapy, improved supportive care, health care reforms, recruitment of trained personnel, and international collaborations. China has made substantial progress treating children with ALL. We envision even better outcomes in the near future.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
02:56Treatment Resistant Cancers